Metagenomi Therapeutics (MGX) Return on Equity (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Return on Equity data on file, last reported at 0.01% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.01%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (changed 0.0% YoY), and the FY2025 annual result was 0.0%, up 1.0% from the prior year.
• Return on Equity eased to 0.01% in Q1 2026 per MGX's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Equity peaked at 0.01% in Q4 2023 and troughed at 0.01% in Q1 2024.
• A 4-year average of 0.0% and a median of 0.0% in 2025 frame the typical range for Return on Equity.
• The sharpest annual moves came in 2024 and 2025: Return on Equity decreased 1 bps in 2024, then rose 1 bps in 2025.
• A 4-year view of Return on Equity shows it stood at 0.01% in 2023, then sank by 134 bps to 0.0% in 2024, then tumbled by 64 bps to 0.01% in 2025, then dropped by 11 bps to 0.01% in 2026.
• Business Quant data shows MGX's Return on Equity at 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.0% in Q3 2025.